76.44 +0.26 (0.34%)
Before hours: 4:51AM EDT
|Bid||76.30 x 1400|
|Ask||76.97 x 800|
|Day's range||76.02 - 77.73|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||16.82|
|Earnings date||27 Oct 2020|
|Forward dividend & yield||2.44 (3.20%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||95.89|
MRK earnings call for the period ending September 30, 2020.
The earnings reports coming out of Dow components were positive, but that wasn't enough to overcome pandemic fears.
Merck was late to join the race to develop a vaccine to protect against the virus, which is again surging in many parts of the world including the United States. Rivals Pfizer Inc, AstraZeneca Plc and Moderna Inc are already deep into late-stage testing. The company began recruiting trial participants in September for an early-stage study of its COVID-19 vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience.